USA flag logo/image

An Official Website of the United States Government

Novel RNAi therapy for ALS and other Neurodegenerative Disorders

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43NS074671
Solicitation Year:
2011
Solicitation Topic Code:
NINDS
Solicitation Number:
PA10-050
Small Business Information
RXI PHARMACEUTICALS CORPORATION
1500 West Park Drive Suite 210 Westborough, MA 01581-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Novel RNAi therapy for ALS and other Neurodegenerative Disorders
Agency: HHS
Contract: 1R43NS074671-01
Award Amount: $304,559.00
 

Abstract:

DESCRIPTION (provided by applicant): Project Summary / Abstract Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons in the central nervous system. Degeneration of the motor neurons results in paralysis and eventual death, usually due to respiratory failure. In a subset of cases, ALS is caused by dominantly transmitted mutations in the gene encoding cytosolic superoxide dismutase (SOD1). Transgenic expression of mutant SOD1 causes ALS in mice. In thesemice, suppression of expression of the transgene using either antisense oligonucleotides or siRNA slows progression and improves survival. While siRNA-based drugs represent a potential therapeutic paradigm for the treatment of CNS and other disorders, theability to apply this technology to human disease has been impeded by the absence of efficient and non-toxic in vivo delivery systems. We have recently developed a novel class of covalently modified RNAi compounds that do not require a delivery vehicle toenter cells and have improved pharmacology compared to traditional siRNAs. We term these compounds self-delivering rxRNA or sd-rxRNATM. sd-rxRNA is a hydrophobically modified RNAi-antisense hybrid, which has been demonstrated to be highly efficacious invivo upon local administration. Robust silencing without toxicity has been demonstrated after intradermal and intravitreal injection, where ug doses induce potent and long lasting silencing. We have already identified an sd-rxRNA compound targeting the SOD1 gene and have demonstrated delivery to spinal cord using implanted intrathecal pumps. Intrathecal administration is a clinically relevant delivery mode that has been used previously for ALS. The objective of this proposal is to optimize and characterizesd-rxRNA technology for gene silencing in spinal cord and development of SOD1 targeting therapeutics for treatment of ALS. PUBLIC HEALTH RELEVANCE: Narrative RNAi (RNA interference) has the potential to treat human disease by down-regulation ofdisease causing genes. However, efficient delivery is a major road block for therapeutic development of RNAi. We have recently developed chemically modified RNAi compounds that enter cells in vivo ( self-delivering RNAi compounds). This project will explore the use of these compounds in spinal cord delivery, in particular for silencing of SOD1 in familial cases of ALS.

Principal Investigator:

Anastasia Khvorova
508-767-3861
akhvorova@rxipharma.com

Business Contact:

Margaret Halfpenny
508-929-3650
mhalfpenny@rxipharma.com
Small Business Information at Submission:

RXI PHARMACEUTICALS CORPORATION
60 PRESCOTT ST WORCESTER, MA -

EIN/Tax ID: 120809951
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No